Camurus AB
STO:CAMX

Watchlist Manager
Camurus AB Logo
Camurus AB
STO:CAMX
Watchlist
Price: 596 SEK 0.59%
Market Cap: 35.7B SEK

EV/EBITDA
Enterprise Value to EBITDA

33.8
Current
52.3
Median
13
Industry
Lower than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
33.8
=
Enterprise Value
32B SEK
/
EBITDA
949.1m SEK
All Countries
Close
Market Cap EV/EBITDA
SE
Camurus AB
STO:CAMX
35.5B SEK 33.8
US
Eli Lilly and Co
NYSE:LLY
999.6B USD 36.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 3 846.3
US
Johnson & Johnson
NYSE:JNJ
501.2B USD 16.3
CH
Roche Holding AG
SIX:ROG
254.4B CHF 11.5
UK
AstraZeneca PLC
LSE:AZN
210.1B GBP 108.3
CH
Novartis AG
SIX:NOVN
206.7B CHF 11.5
US
Merck & Co Inc
NYSE:MRK
250.5B USD 9.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 9.1
IE
Endo International PLC
LSE:0Y5F
209B USD 331.1
US
Pfizer Inc
NYSE:PFE
142.4B USD 7.4
EBITDA Growth EV/EBITDA to Growth
SE
Camurus AB
STO:CAMX
Average EV/EBITDA: 401.9
33.8
72%
0.5
US
Eli Lilly and Co
NYSE:LLY
36.4
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.3
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.5
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.3
10%
10.8
CH
Novartis AG
SIX:NOVN
11.5
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.4
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.1
2%
4.6
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
1%
7.4

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
31
2-Years Forward
EV/EBITDA
18.5
3-Years Forward
EV/EBITDA
12.9